Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
89 studies found for:    "Salivary Gland Neoplasms"
Show Display Options
Rank Status Study
1 Recruiting Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors
Conditions: Salivary Gland Tumors;   Head and Neck Cancer
Interventions: Drug: Docetaxel;   Radiation: Intensity-modulated radiotherapy;   Drug: Pemetrexed;   Drug: Cisplatin
2 Recruiting Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors
Conditions: Salivary Gland Tumors;   Head and Neck Cancer
Interventions: Drug: Cisplatin;   Drug: Docetaxel;   Radiation: Intensity-modulated radiotherapy
3 Completed A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Condition: Malignant Salivary Gland Tumors
Interventions: Drug: Cisplatin: 40 mg/m2 weekly during radiation;   Radiation: Radiation: 60-66 Gy in 2 Gy daily fractions
4 Recruiting Abiraterone Acetate in Patients With Relapsed and/or Metastatic Salivary Gland Cancers
Condition: Salivary Glands Tumors
Intervention: Drug: Abiraterone acetate
5 Completed Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor
Condition: Head and Neck Cancer
Interventions: Drug: carboplatin;   Drug: cisplatin;   Drug: gemcitabine hydrochloride
6 Recruiting Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery
Condition: Head and Neck Cancer
Interventions: Drug: cisplatin;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
7 Recruiting A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes
Conditions: Salivary Gland Cancer;   Metastatic;   Advanced;   Recurrent
Interventions: Drug: Selinexor;   Drug: EGFR or HER2 Inhibitor;   Drug: FGFR Inhibitor;   Drug: C-KIT Inhibitor;   Drug: Anti-androgen;   Drug: NOTCH Inhibitor;   Drug: MEK or PI3K Inhibitor
8 Recruiting Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample
Conditions: Breast Cancer;   Stomach Neoplasms;   Salivary Gland Neoplasms;   Thyroid Cancer
Intervention:
9 Withdrawn Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Conditions: Adenoma, Pleomorphic;   Mixed Salivary Gland Tumor;   Salivary Gland Tumor, Mixed;   Syringoma, Chondroid
Interventions: Radiation: Radiation;   Drug: Panitumumab
10 Recruiting Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14
Condition: Salivary Gland Cancers
Intervention: Drug: Axitinib
11 Recruiting Study of I-125 Brachytherapy Versus Intensity-modulated Radiation Therapy to Treat Inoperable Salivary Gland Cancer
Condition: Salivary Gland Cancer
Interventions: Radiation: brachytherapy;   Radiation: IMRT
12 Recruiting Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
Condition: Salivary Gland Cancer
Interventions: Drug: bicalutamide + triptorelin;   Drug: Cisplatin + Doxorubicin;   Drug: Carboplatin + Paclitaxel
13 Unknown  Activity of Sorafenib in Salivary Gland Cancer
Condition: Salivary Gland Cancer
Intervention: Drug: Sorafenib
14 Active, not recruiting Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer
Conditions: Recurrent Salivary Gland Cancer;   Stage IVA Salivary Gland Cancer;   Stage IVB Salivary Gland Cancer;   Stage IVC Salivary Gland Cancer
Intervention: Drug: eribulin mesylate
15 Completed Iressa Study in Patients With Salivary Gland Cancer
Condition: Salivary Gland Cancer
Intervention: Drug: Gefitinib
16 Active, not recruiting
Has Results
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Conditions: High-grade Salivary Gland Mucoepidermoid Carcinoma;   Low-grade Salivary Gland Mucoepidermoid Carcinoma;   Recurrent Salivary Gland Cancer;   Salivary Gland Acinic Cell Tumor;   Salivary Gland Adenocarcinoma;   Salivary Gland Adenoid Cystic Carcinoma;   Salivary Gland Anaplastic Carcinoma;   Salivary Gland Malignant Mixed Cell Type Tumor;   Salivary Gland Poorly Differentiated Carcinoma;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Salivary Gland Cancer
Interventions: Drug: dasatinib;   Other: laboratory biomarker analysis
17 Completed Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers
Conditions: High-grade Salivary Gland Carcinoma;   High-grade Salivary Gland Mucoepidermoid Carcinoma;   Low-grade Salivary Gland Carcinoma;   Low-grade Salivary Gland Mucoepidermoid Carcinoma;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Salivary Gland Cancer;   Salivary Gland Acinic Cell Tumor;   Salivary Gland Adenocarcinoma;   Salivary Gland Adenoid Cystic Carcinoma;   Salivary Gland Malignant Mixed Cell Type Tumor
Interventions: Drug: lapatinib ditosylate;   Other: laboratory biomarker analysis
18 Active, not recruiting Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck
Condition: Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck
Intervention: Drug: BIBF1120
19 Active, not recruiting Phase II Study of Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma
Condition: Salivary Gland Carcinoma
Intervention: Drug: pazopanib
20 Unknown  Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Salivary Gland Cancer That Cannot Be Removed By Surgery
Condition: Head and Neck Cancer
Interventions: Drug: capecitabine;   Drug: oxaliplatin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.